Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients With Relapsed and/or Refractory Multiple Myeloma (MM)

被引：0
|
作者：
Singhal, Seema B. [1 ]
Siegel, David Samuel diCapua [2 ]
Martin, Thomas [3 ]
Vij, Ravi [4 ]
Wang, Michael [5 ]
Jakubowiak, Andrzej J. [6 ]
Lonial, Sagar [7 ]
Kukreti, Vishal [8 ]
Zonder, Jeffrey A. [9 ]
Wong, Alvin F. [10 ]
McCulloch, Leanne [10 ]
Kauffman, Michael [10 ]
Badros, Ashraf Z. [11 ]
Niesvizky, Ruben [12 ]
Orlowski, Robert Z. [13 ]
Stewart, A. Keith [14 ]
Jagannath, Sundar [15 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Div Hem Onc, Chicago, IL 60611 USA
[2] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[3] Univ San Francisco, San Francisco, CA 94117 USA
[4] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA
[5] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[7] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[8] Princess Margaret Hosp, Div Hematol Oncol, Toronto, ON M4X 1K9, Canada
[9] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[10] Onyx Pharmaceut, Emeryville, CA USA
[11] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[12] Weill Cornell Med Coll, New York, NY USA
[13] Univ Texas Houston, MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA
[14] Mayo Clin Arizona, Scottsdale, AZ USA
[15] Mt Sinai Med Ctr, Multiple Myeloma Program, New York, NY 10029 USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：814 / 815
页数：2
相关论文
共 50 条
  • [21] A Phase 3 Study of Carfilzomib and Dexamethasone (Kd) in Patients With Relapsed and Refractory Multiple Myeloma (MM) in China
    Du, Juan
    Fang, Baijun
    Li, Jian
    Jin, Jie
    Wang, Shunqing
    Zou, Dehui
    Cai, Zhen
    Wang, Hongxiang
    Hu, Jianda
    Li, Wei
    Fu, Chengcheng
    Shao, Zonghong
    Xia, Zhongjun
    Liu, Peng
    Niu, Ting
    Tang, En-Tzu
    Kimball, Amy
    Hou, Jian
    Chen, Wenming
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E267 - E268
  • [22] A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Hans C. Lee
    Jatin J. Shah
    Lei Feng
    Elisabet E. Manasanch
    Rebecca Lu
    Ashley Morphey
    Brandon Crumpton
    Krina K. Patel
    Michael L. Wang
    Raymond Alexanian
    Sheeba K. Thomas
    Donna M. Weber
    Robert Z. Orlowski
    Blood Cancer Journal, 9
  • [23] A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Lee, Hans C.
    Shah, Jatin J.
    Feng, Lei
    Manasanch, Elisabet E.
    Lu, Rebecca
    Morphey, Ashley
    Crumpton, Brandon
    Patel, Krina K.
    Wang, Michael L.
    Alexanian, Raymond
    Thomas, Sheeba K.
    Weber, Donna M.
    Orlowski, Robert Z.
    BLOOD CANCER JOURNAL, 2019, 9 (10)
  • [24] Long-Term Treatment and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)
    Jagannath, Sundar
    Vij, Ravi
    Kaufman, Jonathan L.
    Martin, Thomas
    Niesvizky, Ruben
    Gabrail, Nashat Y.
    Alsina, Melissa
    Wong, Alvin F.
    Le, Mai H.
    McCulloch, Leanne
    Hannah, Alison L.
    Kauffman, Michael
    Siegel, David Samuel diCapua
    BLOOD, 2010, 116 (21) : 814 - 814
  • [25] Efficacy and safety of elranatamab in Japanese patients with relapsed/refractory multiple myeloma (RRMM): a pooled analysis from the MagnetisMM studies
    Ishida, Tadao
    Yokoyama, Hisayuki
    Suzuki, Kenshi
    Ito, Satoshi
    Nagai, Yuya
    Handa, Hiroshi
    Ito, Shigeki
    Kamei, Yoichi
    Nakamura, Masatoshi
    Viqueira, Andrea
    White, Jane Liang
    Take, Kazumi
    Moribe, Toyoki
    Iida, Shinsuke
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S186 - S187
  • [26] Safety profile of single-agent carfilzomib in patients with relapsed or refractory multiple myeloma from 4 phase 2 trials
    Siegel, D. S.
    Martin, T.
    Nooka, A.
    Harvey, R. D.
    Vij, R.
    Niesvizky, R.
    Badros, A. Z.
    Jagannath, S.
    McCulloch, L.
    Rajangam, K.
    Lonial, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 : 20 - 20
  • [27] BUDGET IMPACT ANALYSIS OF CARFILZOMIB FOR THE TREATMENT OF RELAPSED REFRACTORY MULTIPLE MYELOMA (MM) IN MEXICO
    Alva, M. E.
    Campioni, M.
    Zamora, J.
    Giannopoulou, A.
    VALUE IN HEALTH, 2015, 18 (07) : A818 - A818
  • [28] Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma
    Stewart, A. Keith
    FUTURE ONCOLOGY, 2015, 11 (15) : 2121 - 2136
  • [29] Phase II Study of Infusional Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma
    Lendvai, Nikoletta
    Landau, Heather
    Lesokhin, Alexander
    Tsakos, Ioanna
    Koehne, Guenther
    Chung, David
    Devlin, Sean
    Hassoun, Hani
    Giralt, Sergio A.
    BLOOD, 2012, 120 (21)
  • [30] A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM).
    Moreau, P.
    Palumbo, A. P.
    Stewart, A. K.
    Rajkumar, V.
    Jakubowiak, A. J.
    Halka, K.
    Goranov, S.
    Bumbea, H.
    Pendergrass, K. B.
    Lupu, A.
    Dimopoulos, A.
    Rocafiguera, A. O.
    Gandhi, J. G.
    Mihaylov, G.
    Masszi, T.
    Matous, J.
    Fonseca, G.
    Bryce, R.
    Siegel, D. S. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345